CN113975190A - 一种美白组合物及其应用 - Google Patents
一种美白组合物及其应用 Download PDFInfo
- Publication number
- CN113975190A CN113975190A CN202110976328.7A CN202110976328A CN113975190A CN 113975190 A CN113975190 A CN 113975190A CN 202110976328 A CN202110976328 A CN 202110976328A CN 113975190 A CN113975190 A CN 113975190A
- Authority
- CN
- China
- Prior art keywords
- whitening
- stirring
- hydroxyapatite
- homogenizing
- glutathione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 claims abstract description 19
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 18
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 18
- 108010024636 Glutathione Proteins 0.000 claims abstract description 17
- 229960003180 glutathione Drugs 0.000 claims abstract description 17
- 235000001014 amino acid Nutrition 0.000 claims abstract description 12
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 239000003381 stabilizer Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000018417 cysteine Nutrition 0.000 claims abstract description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 7
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims abstract description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 6
- 108010020346 Polyglutamic Acid Proteins 0.000 claims abstract description 6
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 6
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001631 carbomer Drugs 0.000 claims abstract description 6
- 229920001577 copolymer Polymers 0.000 claims abstract description 6
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940078492 ppg-17 Drugs 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims abstract description 6
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 3
- 229920000570 polyether Polymers 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims description 19
- 239000011259 mixed solution Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 230000007794 irritation Effects 0.000 abstract description 14
- 230000008859 change Effects 0.000 abstract description 5
- 230000001276 controlling effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 102000016611 Proteoglycans Human genes 0.000 description 11
- 108010067787 Proteoglycans Proteins 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229910052586 apatite Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000004383 yellowing Methods 0.000 description 2
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241001085205 Prenanthella exigua Species 0.000 description 1
- 241001326934 Triarrhena Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种美白组合物及其应用。本发明还公开了一种采用上述美白组合物制备的美白化妆品,该美白化妆品包括以下质量百分比的组分:谷胱甘肽0‑2%、羟基磷灰石0‑5%、氨基酸稳定剂0‑2%、蛋白多糖0‑1%、4‑丁基间苯二酚0‑2%、甘油0‑5%、甲基丙二醇0‑4%、丁二醇0‑2%、1,2戊二醇0‑2%、聚谷氨酸钠0‑0.1%、卡波姆0‑0.2%、鞘氨醇菌胶0‑0.2%、甘油聚醚‑260‑2%、PEG/PPG‑17/6共聚物0‑2%、对羟基苯乙酮0‑0.5%、余量水。本发明通过调控美白组合物中羟基磷灰石/半胱氨酸/蛋白多糖的比例,组分间协同配伍,能够消除谷胱甘肽的臭味,同时稳定4‑丁基间苯二酚并增加其稳定性、降低其刺激性;确保获得的美白产品气味最小、颜色变化最小、刺激性最小、美白效果最好,各方面性能达到最佳。
Description
技术领域
本发明涉及护肤品技术领域,尤其涉及一种美白组合物及其应用。
背景技术
随着美白祛斑市场的日渐火爆,由于目前市面上美白祛斑产品低效、副作用大、产品稳定性难度大等,因此一般需要通过医疗手段进行美白祛斑,例如:激光、水光针、刷酸换肤等。
现有技术中各种常用美白剂的缺点:1、谷胱甘肽是由谷氨酸、半胱氨酸和甘氨酸结合、且含有巯基的的三肽,其具有抗氧化作用和整合解毒作用,能消除人体自由基,提高人体免疫力。美国Merle Norman发布的谷胱甘肽,采用了肌肤色素研究中最新的科学技术,研发出独家“谷胱甘肽(Baidi peptide)与高浓度苦参精华(Radix sophoraeflavescentis)”以及其他一些独特成分的多重效果配方,可由内而外双重锁定麦拉宁母细胞,让女人恢复珍珠般的亮白肤质,并且能够淡化顽固的色斑。相比一般的产品而言,白荻多肽就像是一把精密的高端“美白锁”,能够紧密地锁住酪氨酸酶,阻止酪氨酸的渗透,以此来达到抑制黑色素形成的目的。谷胱甘肽是美国Merle Norman经典作品,风行欧美50年,堪称世纪美白祛斑经典。但是,谷胱甘肽用于化妆品后稳定性不好,会产生难闻的气味,影响使用感;2、4-丁基间苯二酚是一种化学物质,常用做护肤产品美白添加剂,是酪氨酸和过氧化物酶的强抑制剂。但该成分对皮肤的刺激性太大,容易导致皮肤过敏。而且此类型的成分对光和热等因素敏感,含有该成分的产品易变色,影响产品的稳定性;3、苯乙基间苯二酚/熊果苷/烟酰胺等的刺激性和不稳定性,维生素C及其衍生物的不稳定性、刺激性。
羟基磷灰石:又称羟磷灰石,碱式磷酸钙,是钙磷灰石的自然矿物化,经常被写成(Ca10(PO4)6(OH)2)的形式以突出它是由羟基与磷灰石两部分组成的。羟基磷灰石是目前研究最多的生物材料之一,该材料中含有人体正常新陈代谢所需要的元素,在生理环境中逐步的降解和吸收,或与肌体组织之间形成稳定的化学键合。人工合成的羟基磷灰石还可以用作荧光材料、生物大分子色谱分离剂、催化剂、吸附剂、药物载体等。羟基磷灰石对金属离子和生物大分子都有良好的吸附性。其与有机物质的吸附是个很复杂的过程,主要通过表面吸附,吸附过程通过静电效应(范德华力)。吸附后具有稳定被吸附的物质的作用,同时亦可以在某些条件下释放被吸附的物质。
半胱氨酸:一种生物体内常见的氨基酸,存在于许多蛋白质、谷胱甘肽中。在皮肤蛋白的角蛋白生成中维持重要的琉基酶的活性,并且补充硫基,以维持皮肤的正常代谢,调节表皮最下层的色素细胞生成的底层黑色素,是一种非常理想的自然美白化妆品。它可以除去皮肤本身的黑色素,改变皮肤本身的性质,使皮肤变得自然的美白。
蛋白多糖:结缔组织基质中蛋白质与多糖以共价和非共价键相连构成多种巨大分子称为蛋白多糖(proteoglycans)或粘蛋白(mucoproteins)。其分子组成以多糖链为主,蛋白质部分所占比例较小。往往一条多糖链上联结多条多肽链,分子量可达数百万以上。常见蛋白多糖有聚集素、乙聚糖、装饰素、渗滤素、丝甘素、联合素-1。
因此,迫切需要开发一种效果好、稳定性好、刺激性低的美白产品。
发明内容
本发明的目的是针对现有技术中的不足,提供一种美白组合物及其应用,该美白组合物中的羟基磷灰石具有吸附作用,能够稳定谷胱甘肽和4-丁基间苯二酚,避免或者减少美白产品出现异味、变色,同时降低刺激性;同时氨基酸和蛋白多糖也可以进一步增加组合物的稳定性。
为实现上述目的,本发明采取的技术方案是:
本发明第一方面提供一种美白组合物,所述组合物包括以下质量百分比的组分:谷胱甘肽0-2%、羟基磷灰石0-5%、氨基酸稳定剂0-2%、4-丁基间苯二酚0-2%、蛋白多糖0-1%、余量水;其中,所述氨基酸稳定剂为半胱氨酸。
本发明第二方面是提供一种采用上述美白组合物制备的美白化妆品,所述美白化妆品包括以下质量百分比的组分:谷胱甘肽0-2%、羟基磷灰石0-5%、氨基酸稳定剂0-2%、蛋白多糖0-1%、4-丁基间苯二酚0-2%、甘油0-5%、甲基丙二醇0-4%、丁二醇0-2%、1,2戊二醇0-2%、聚谷氨酸钠0-0.1%、卡波姆0-0.2%、鞘氨醇菌胶0-0.2%、甘油聚醚-260-2%、PEG/PPG-17/6共聚物0-2%、对羟基苯乙酮0-0.5%、余量水。
本发明第三方面提供上述美白化妆品的制备方法,包括如下步骤:
S1、按比例称取所述丁二醇、1,2-戊二醇、鞘氨醇菌胶、聚谷氨酸钠、谷胱甘肽、羟基磷灰石、氨基酸稳定剂、4-丁基间苯二酚和蛋白多糖,搅拌混匀,均质处理后,密封保存,制得混合溶液一;
S2、按比例在乳化锅中加入所述甘油、甲基丙二醇和对羟基苯乙酮,加热搅拌至所述对羟基苯乙酮完全溶解;然后,按比例在所述乳化锅中继续加入所述水、卡波姆、甘油聚醚-26、PEG/PPG-17/6共聚物,搅拌成无色透明粘稠状液体,制得混合溶液二;
S3、快速搅拌条件下将经步骤S1制得的所述混合溶液一缓慢加入到经步骤S2制得的所述混合溶液二中,添加完毕后均质处理,继续搅拌一段时间;出料。
优选地,步骤S1中,所述搅拌时间为1-2小时。
优选地,步骤S1中,所述均质转速为3000-3500转/分,均质时间为1-2分钟。
优选地,步骤S1中,所述密封保存时间为12-15小时。
优选地,步骤S3中,所述均质转速为3000-3500转/分,均质时间为1-2分钟。
优选地,步骤S3中,所述搅拌时间为1-2小时。
本发明采用以上技术方案,与现有技术相比,具有如下技术效果:
本发明通过调控美白组合物中羟基磷灰石/半胱氨酸/蛋白多糖的比例,组分间协同配伍,能够消除谷胱甘肽的臭味,同时稳定4-丁基间苯二酚并增加其稳定性、降低其刺激性;确保获得的美白产品气味最小、颜色变化最小、刺激性最小、美白效果最好,各方面性能达到最佳。
具体实施方式
下面结合具体实施例对本发明作进一步说明,但不作为本发明的限定。需要说明的是,在不冲突的情况下,本发明中的实施例及实施例中的特征可以相互组合。
实施例
本实施例提供了一种美白化妆品的制备方法,包括如下步骤:
S1、称取丁二醇、1,2-戊二醇、鞘氨醇菌胶、甘油聚醚-26、谷胱甘肽、羟基磷灰石、氨基酸稳定剂、4-丁基间苯二酚和蛋白多糖,搅拌1-2小时后混合均匀,3000-3500转/分、均质1-2分钟后,密封保存12-15小时,制得混合溶液一;
S2、在乳化锅中加入甘油、甲基丙二醇和对羟基苯乙酮,加热搅拌至对羟基苯乙酮完全溶解;然后,在上述乳化锅中继续加入水、聚谷氨酸钠、卡波姆和PEG/PPG-17/6共聚物,搅拌成无色透明粘稠状液体,制得混合溶液二;
S3、快速搅拌条件下将经步骤S1制得的混合溶液一缓慢加入到经步骤S2制得的混合溶液二中,添加完毕后3000-3500转/分、均质1-2分钟,继续搅拌1-2小时;出料。
采用上述制备方法分别制备得到1#~6#号的美白化妆品以及作为对照品的美白化妆品,其组分以及组分的质量百分比如表1所示:
表1
应用例
(1)对上述实施例制备的1#~6#号的美白化妆品以及作为对照品的美白化妆品进行气味浓度验证,5位嗅觉正常试用者根据气味轻重程度打分,0-5分,异味越重,分值越高;0代表基本无异味,5代表异味最重,其结果如表2所示:
表2
1# | 2# | 3# | 4# | 5# | 6# | 对照品 | |
试用者1 | 0 | 1 | 2 | 3 | 3 | 4 | 5 |
试用者2 | 0 | 1 | 2 | 2 | 2 | 3 | 5 |
试用者3 | 1 | 0 | 1 | 2 | 2 | 3 | 5 |
试用者4 | 0 | 0 | 2 | 3 | 3 | 4 | 5 |
试用者5 | 1 | 0 | 1 | 2 | 2 | 3 | 5 |
平均值 | 0.4 | 0.4 | 1.6 | 2.4 | 2.4 | 3.4 | 5 |
(2)对上述实施例制备的1#~6#号的美白化妆品以及作为对照品的美白化妆品进行颜色变化验证,同时暴晒在太阳下30天,观察料体颜色变黄程度,0-5分打分,分值越高,变黄越明显,其结果如表3所示:
表3
1# | 2# | 3# | 4# | 5# | 6# | 对照品 | |
第1天 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
第10天 | 0 | 0 | 1 | 1 | 1 | 2 | 3 |
第20天 | 1 | 1 | 2 | 3 | 3 | 4 | 5 |
第30天 | 1 | 1 | 3 | 4 | 4 | 5 | 5 |
(3)对上述实施例制备的1#号的美白化妆品以及作为对照品的美白化妆品进行美白效果验证,结果如表4所示:
测试仪器:Minolta色度仪CR400
测试时间:40天(每天早晚两次使用)
试用者:24位,年龄25-55岁。
产品使用方法:24位试用者左侧脸涂抹1#号的美白化妆品,右侧脸涂抹对照品,连续使用40天,测24位试用者两侧脸亮度的平均值
表4
亮度 | 实施例1(左侧脸) | 对比例(右侧脸) |
第1天 | 54 | 54 |
第40天 | 58 | 58 |
(4)对上述实施例制备的1#~6#号的美白化妆品以及作为对照品的美白化妆品进行刺激性验证,5位健康肤质的试用者根据刺激性轻重程度打分,0-5分,刺激性越强,分值越高;0代表基本无刺激,5代表刺激性最重,其结果如表5所示:
表5
1# | 2# | 3# | 4# | 5# | 6# | 对照品 | |
试用者1 | 0 | 1 | 2 | 1 | 1 | 2 | 4 |
试用者2 | 0 | 1 | 3 | 1 | 1 | 2 | 5 |
试用者3 | 1 | 0 | 2 | 1 | 1 | 2 | 5 |
试用者4 | 0 | 1 | 2 | 1 | 2 | 3 | 4 |
试用者5 | 1 | 1 | 3 | 2 | 2 | 3 | 5 |
平均值 | 0.4 | 0.8 | 2.4 | 1.2 | 1.4 | 2.4 | 4.6 |
从表5可见,在未加抗敏剂的情况下,4-丁基间苯二酚添加量2%时,一般人会感觉明显的刺痛感。羟基磷灰石可以有效降低4-丁基间苯二酚的刺激性,且羟基磷灰石含量越高,降低刺激越明显;半胱氨酸和蛋白多糖对降低4-丁基间苯二酚刺激性影响稍弱。
以上所述仅为本发明较佳的实施例,并非因此限制本发明的实施方式及保护范围,对于本领域技术人员而言,应当能够意识到凡运用本发明说明书内容所作出的等同替换和显而易见的变化所得到的方案,均应当包含在本发明的保护范围内。
Claims (8)
1.一种美白组合物,其特征在于,所述组合物包括以下质量百分比的组分:谷胱甘肽0-2%、羟基磷灰石0-5%、氨基酸稳定剂0-2%、蛋白多糖0-1%、4-丁基间苯二酚0-2%、余量水;其中,所述氨基酸稳定剂为半胱氨酸。
2.一种采用如权利要求1所述的美白组合物制备的美白化妆品,其特征在于,所述美白化妆品包括以下质量百分比的组分:谷胱甘肽0-2%、羟基磷灰石0-5%、氨基酸稳定剂0-2%、蛋白多糖0-1%、4-丁基间苯二酚0-2%、甘油0-5%、甲基丙二醇0-4%、丁二醇0-2%、1,2戊二醇0-2%、聚谷氨酸钠0-0.1%、卡波姆0-0.2%、鞘氨醇菌胶0-0.2%、甘油聚醚-260-2%、PEG/PPG-17/6共聚物0-2%、对羟基苯乙酮0-0.5%、余量水。
3.一种如权利要求2所述的美白化妆品的制备方法,其特征在于,包括如下步骤:
S1、按比例称取所述丁二醇、1,2-戊二醇、鞘氨醇菌胶、甘油聚醚-26、谷胱甘肽、羟基磷灰石、氨基酸稳定剂、4-丁基间苯二酚和蛋白多糖,搅拌混匀,均质处理后,密封保存,制得混合溶液一;
S2、按比例在乳化锅中加入所述甘油、甲基丙二醇和对羟基苯乙酮,加热搅拌至所述对羟基苯乙酮完全溶解;然后,按比例在所述乳化锅中继续加入所述水、聚谷氨酸钠、卡波姆和PEG/PPG-17/6共聚物,搅拌成无色透明粘稠状液体,制得混合溶液二;
S3、快速搅拌条件下将经步骤S1制得的所述混合溶液一缓慢加入到经步骤S2制得的所述混合溶液二中,添加完毕后均质处理,继续搅拌一段时间;出料。
4.根据权利要求3所述的制备方法,其特征在于,步骤S1中,所述搅拌时间为1-2小时。
5.根据权利要求3所述的制备方法,其特征在于,步骤S1中,所述均质转速为3000-3500转/分,均质时间为1-2分钟。
6.根据权利要求3所述的制备方法,其特征在于,步骤S1中,所述密封保存时间为12-15小时。
7.根据权利要求3所述的制备方法,其特征在于,步骤S3中,所述均质转速为3000-3500转/分,均质时间为1-2分钟。
8.根据权利要求3所述的制备方法,其特征在于,步骤S3中,所述搅拌时间为1-2小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110976328.7A CN113975190A (zh) | 2021-08-24 | 2021-08-24 | 一种美白组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110976328.7A CN113975190A (zh) | 2021-08-24 | 2021-08-24 | 一种美白组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113975190A true CN113975190A (zh) | 2022-01-28 |
Family
ID=79735208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110976328.7A Pending CN113975190A (zh) | 2021-08-24 | 2021-08-24 | 一种美白组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113975190A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317436A (zh) * | 2022-10-14 | 2022-11-11 | 广州优理氏生物科技有限公司 | 一种具有温和美白祛斑作用的组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110115694A (zh) * | 2019-05-23 | 2019-08-13 | 中山市粤美医疗生物科技有限公司 | 一种具有美白、祛斑作用的精华液 |
CN110934755A (zh) * | 2019-12-20 | 2020-03-31 | 广州市拉凯尔干细胞研究所 | 一种含有氯氧化铋的美白保湿霜的制备方法 |
CN112315890A (zh) * | 2020-11-24 | 2021-02-05 | 北京鸣聚力商贸有限责任公司 | 一种美白亮肤组合物及其制备方法和应用 |
-
2021
- 2021-08-24 CN CN202110976328.7A patent/CN113975190A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110115694A (zh) * | 2019-05-23 | 2019-08-13 | 中山市粤美医疗生物科技有限公司 | 一种具有美白、祛斑作用的精华液 |
CN110934755A (zh) * | 2019-12-20 | 2020-03-31 | 广州市拉凯尔干细胞研究所 | 一种含有氯氧化铋的美白保湿霜的制备方法 |
CN112315890A (zh) * | 2020-11-24 | 2021-02-05 | 北京鸣聚力商贸有限责任公司 | 一种美白亮肤组合物及其制备方法和应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317436A (zh) * | 2022-10-14 | 2022-11-11 | 广州优理氏生物科技有限公司 | 一种具有温和美白祛斑作用的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101779905B1 (ko) | 충전제와 섬유아세포 성장 배지를 조합한 주사용 조성물 | |
JP2649531B2 (ja) | 化粧学的活性物質と結合した有機シリコン化合物からなる生成物 | |
WO2006080768A1 (en) | Anti-aging cosmetic composition | |
CN109512691A (zh) | 一种蓝铜肽冻干粉制剂及其制备方法 | |
WO2006083072A1 (en) | Composition of skin external application containing rose extract and epigallocatechin gallate(egcg) | |
CN107814853A (zh) | 适合用于美容和药物用途的外用透皮糖胺聚糖制剂 | |
CN113975190A (zh) | 一种美白组合物及其应用 | |
EP2136771B1 (en) | Compositions containing n-acetylglucosamine for use in dermo-cosmetology and aesthetic medicine | |
US20030103960A1 (en) | Sealant and bone generating product | |
JP2023097373A (ja) | シゾフィランの組成物及びその調製方法および応用 | |
CN104013537B (zh) | 填充剂的效能维持用组合物 | |
WO2019211567A1 (fr) | Composition comprenant de l'acide alpha-lipoique ou l'un de ses sels, un derive de vitamine c et de l'acide hyaluronique et son utilisation | |
KR20080068077A (ko) | 섬유아세포 활성화제 및 섬유아세포 활성화 방법, 콜라겐합성 촉진제 및 콜라겐 합성 촉진 방법, 및 피부 노화방지제 및 피부 노화 방지 방법 | |
KR20060030142A (ko) | 펩타이드 성분들을 포함하는 화장용 조성물 | |
KR20190005653A (ko) | 피부 재생용 화장료 조성물 | |
RU2144815C1 (ru) | Способ получения регенерирующего косметического крема для ухода за кожей | |
RU2142785C1 (ru) | Косметическое средство для ухода за кожей "гармония-n" или "гармония-r" | |
KR20090028275A (ko) | 에센셜 오일 조합을 주성분으로 하는피부 노화방지와주름개선 효과를 갖는 화장료 및 그 제조방법 | |
CN111840127A (zh) | 一种兼具抗衰阻糖作用的自由基清除剂及制备方法 | |
US20040234476A1 (en) | Cosmetic preparation with anti-wrinkle action | |
KR102549636B1 (ko) | Egf의 피부 흡수 증진용 화장료 조성물 | |
KR101611134B1 (ko) | 피부 재생용 화장품의 제조방법 | |
CN112353789B (zh) | 一种化妆品 | |
KR101609217B1 (ko) | 해파리로부터 당단백질을 제조하는 방법 및 그 당단백질을 함유하는 화장료 조성물 | |
KR102608639B1 (ko) | 캡슐화케라틴의 제조방법 및 이의 방법으로 제조된 캡술화케라틴을 포함하는 피부장벽 개선용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220128 |
|
RJ01 | Rejection of invention patent application after publication |